⌕
Belite Bio · BLTE · Nasdaq
Tenet 68 · Solid
Compare
$164.36−3.30%At closeTenet 68 · Solid
$164.36−5.61 (−3.30%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Belite Bio (BLTE) Stock

Belite Bio (BLTE) closed at $164.36 on Nov 13, 2026; its Tenet Score is 68 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

32 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$164.36
Nov 13, 2026
Market cap
$6.5Bunverified basis
share basis not confirmed
52-week range
105.88 – 200.00
low → high
Tenet Score
68/100
Solid · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Belite Bio Inc scores 68/100. Solid. Strongest on financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 68 is built from 2 of 4 pillars, from 15% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
68/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
37
Health
100
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value & Growth omitted — no data yet.
Value—QualityDHealthA+Growth—MomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
loss
P/B
8.4×
price to book value
P/S
—
no P/S on file
ROE
−17%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
pre_revenue
Current ratio
—
band_current_ratio
Net debt / EBITDA
—
no_ebitda
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).

The whole report, at a glance · every card is a live peek, click any to open the section

About Belite Bio Inc

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 8 US ETFs · top wrappers by weightSee all ETFs holding BLTE →

What sector and industry is Belite Bio in?

Belite Bio is in the Healthcare sector and the Drugs industry.

What is Belite Bio's Tenet Score?

Belite Bio's Tenet Score is 68 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.